RT Journal Article
SR Electronic
T1 Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP thoraxjnl-2017-210035
DO 10.1136/thoraxjnl-2017-210035
A1 Andrea Gimenez
A1 Karin Storrer
A1 Lilian Kuranishi
A1 Maria Raquel Soares
A1 Rimarcs Gomes Ferreira
A1 Carlos A C Pereira
YR 2017
UL http://thorax.bmj.com/content/early/2017/09/07/thoraxjnl-2017-210035.abstract
AB The predictive value of the decline in FVC by ≥10% on survival in patients with fibrotic hypersensitivity pneumonitis is unknown. Of 112 patients included, 66 (59%) had surgical lung biopsies. Patients with ≥10% decline in predicted FVC after 6–12 months had a significantly increased risk of all-cause mortality (median survival 53 months, 95% CI 37 to 69 vs 139 months, 95% CI 66 to 212 months, p=0.007). On multivariate analysis remained associated with increasing mortality: decline in FVC by ≥10% (HR 4.13, 95% CI 1.96 to 8.70, p=0.005), lower FVC% (HR 1.03 , 95% CI 1.01 to 1.05 , p=0.003) and with decreasing mortality improvement with antigen avoidance (HR 0.18, 95% CI 0.04 to 0.77, p=0.021).